REFERENCES
- Patella F, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med. 1998; 338: 853–860.
- Kumaraswamy N, Solomon S, Chatuguru SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis. 2005; 41: 1525–1528.
- Whitcup S, Fortin E, Nussenblatt RB, Polis MA, Muccioli C, Belfort R. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. J Am Med Assoc. 1997; 277: 1519–1520.
- Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003 Sep; 17(13):1907–1915.
- De Simone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med. 2000 Sep; 133(6):447–445.
- Otiti-Sengeri J, Meenken C, van den Horn GJ, Kempen JH. Ocular immune reconstitution inflammatory syndromes. Curr Opin HIV AIDS. 2008;3(4):432–437.
- Alp MN, Baykam N, Kural G. Immune recovery uveitis associated with highly active antiretroviral therapy in a patient with CMV retinitis and AIDS despite a low CD4+ T cell count: case report and a review of the literature. Int Ophthalmol. 2010;30(2):183–189.
- Saiag P, Caumes E, Chosidow O, et al. Drug induced toxic epidermal necrolyis (Lyell syndrome) in patients with the human immunodeficiency virus. J Am Acad Dermatol. 1992; 26: 567–574.
- Jean-Paul Fagot Mockenhaupt, M, Bouwes-Bavinck JN, et al. Nevirapine and the risk of Stevens Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001;15: 1843–1848.
- Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Steven-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333:1600–1607.
- Jain V, Shome D, Natranjan S. Nevirapine-induced Steven Johnson syndrome in an AIDS patient. Cornea. 2008; 27: 366–367.
- Venkatesh KK, Biswas J, Kumaraswamy N. Impact of highly active antiretroviral therapy on ophthalmic manifestations in human immunodeficiency/acquired immune deficiency syndrome. Indian J Ophthal. 2008; 56: 391–393.
- Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003; 83(1):1–9.